ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Reviews: AURORA 2, & Urinary Biomarkers

Arthritis & Rheumatology  |  November 25, 2025

AURORA 2 Voclosporin, a novel calcineurin inhibitor (CNI), is associated with a favorable metabolic profile with regard to lipids and glucose, and a predictable pharmacokinetic profile, resulting in no need for the therapeutic drug monitoring required of other CNIs. AURORA 2, a double-blind, phase 3 study, evaluated the longterm safety, tolerability and efficacy of voclosporin…

60-Day Comment Period Opens for FDA’s Draft Guidance on Biosimilars

Michele B. Kaufman, PharmD, BCGP  |  November 24, 2025

The FDA has issued draft guidance recommending that all biosimilar medications be designated as interchangeable with their reference products upon initial FDA approval. A 60-day review and comment period of the draft guidance is now open, and the ACR will soon be submitting comments. 

Autoantibodies Illuminate Lupus Nephritis

Arthritis & Rheumatology  |  November 24, 2025

In this study, Fava et al. investigated longitudinal autoantibody profiles in a racially diverse cohort of patients with lupus nephritis to define noninvasive serological biomarkers of histologic class and one-year treatment response to standard of care. In addition, the researchers determined how these biomarkers changed over time to provide further insights into treatment response and…

Case Report: Lupus Nephritis, or a Mimic?

Matthew J. Mandell, DO, FACP, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD  |  November 23, 2025

Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involvement. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis. We present…

Extra Services Can Boost a Rheumatology Practice’s Profitability, Patient Care

Vanessa Caceres  |  November 22, 2025

Rheumatology practices can combat declining reimbursements with ancillary services. Experts discuss adding infusion, ultrasound & research services to boost revenue & patient care.

B Cell-Depleting Therapy in SLE & Lupus Nephritis

Katie Robinson  |  November 22, 2025

“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-Nürnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…

Tips for Recruiting & Onboarding Advanced Practice Providers

Vanessa Caceres  |  November 21, 2025

Experts share strategies for recruiting, onboarding & retaining APPs to address the rheumatologist shortage & improve patient access.

Complications: Renal Arteriosclerosis in Patients with Lupus Nephritis

Mary Beth Nierengarten  |  November 21, 2025

Renal arteriosclerosis is common in patients with lupus nephritis and occurs two decades earlier than it does in people without the condition, say investigators in a study that examined the prevalence of renal arteriosclerosis in patients with lupus nephritis compared with healthy controls.1 The finding suggests that renal arteriosclerosis could be used as a biomarker…

Independent Rheumatology Practices Face Challenges Amid Changing Landscape

Vanessa Caceres  |  November 20, 2025

At this Practice Innovation Summit session, experts discussed the challenges that come with surviving as an independent rheumatology practice in the current health environment.

8 Tips for Hiring and Keeping the Best Employees for Your Practice

Vanessa Caceres  |  November 20, 2025

Even if you hire human resources professionals, as a private practice owner, you still want to have a good grip on the basics of attracting great people to your practice and keeping them happy. Speakers at ACR Convergence 2025 shared pearls to help practice owners do just that.

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 842
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences